Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Arcadia Biosciences (RKDA) over the last 12 years, with Q2 2025 value amounting to $250000.0.

  • Arcadia Biosciences' Cash from Investing Activities fell 9461.56% to $250000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 3308.05%. This contributed to the annual value of $7.3 million for FY2024, which is 26901.47% up from last year.
  • As of Q2 2025, Arcadia Biosciences' Cash from Investing Activities stood at $250000.0, which was down 9461.56% from $500000.0 recorded in Q1 2025.
  • Arcadia Biosciences' 5-year Cash from Investing Activities high stood at $17.4 million for Q2 2021, and its period low was -$4.7 million during Q2 2023.
  • Over the past 5 years, Arcadia Biosciences' median Cash from Investing Activities value was $215000.0 (recorded in 2024), while the average stood at $1.2 million.
  • As far as peak fluctuations go, Arcadia Biosciences' Cash from Investing Activities crashed by 992500.0% in 2023, and later surged by 1240000.0% in 2025.
  • Quarter analysis of 5 years shows Arcadia Biosciences' Cash from Investing Activities stood at -$70000.0 in 2021, then skyrocketed by 501.43% to $281000.0 in 2022, then plummeted by 81.49% to $52000.0 in 2023, then surged by 4736.54% to $2.5 million in 2024, then tumbled by 90.06% to $250000.0 in 2025.
  • Its Cash from Investing Activities stands at $250000.0 for Q2 2025, versus $500000.0 for Q1 2025 and $2.5 million for Q4 2024.